Balaxi Pharmaceuticals Ltd (BALAXI) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: BALAXI | Trading | Small Cap

BSE Share Price
Not Listed

Balaxi Pharmaceuticals Ltd (BALAXI) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: BALAXI | Trading | Small Cap

DeciZen - make an informed investing decision on Balaxi Pharma.

Based on:

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Balaxi Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
48.00
Market Cap:
193.1 Cr.
52-wk low:
0
52-wk high:
0

Is Balaxi Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Balaxi Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Balaxi Pharmaceuticals Ltd is a below average quality company.

2. Is Balaxi Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Balaxi Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Balaxi Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Balaxi Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Balaxi Pharma.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Balaxi Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -2.1%-4.7%-39.7%96.2%58.4%55.4%37.1%28.2%6.1%5.1%-
Value Creation
Index
-1.2-1.3-3.85.93.23.01.71.0-0.6-0.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0.10013.645.686.910110870.26157
Sales YoY Gr.--100%NANA235.5%90.4%16.6%6.8%-35.1%-13.1%-
Adj EPS -0.1-0.1-0.51.31.22.82.62.40.50.30.7
YoY Gr.-NANANA-8.3%129.5%-8.9%-6.7%-81.1%-40%-
BVPS (₹) 2.11.512.35.68.711.616.121.623.223.8
Adj Net
Profit
-0.1-0.2-0.826.11412.812.12.51.54
Cash Flow from Ops. -0-0.1-0.7-1.5-14.413.58.9-7.1-1.8-7.6-
Debt/CF from Ops. -5.800000.30.2-1.5-7.6-4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 120.3%6%-15.6%-13.1%
Adj EPS NA-26%-52.7%-40%
BVPS30.8%32.7%26%7.2%
Share Price - -44.2% -60.9% -58.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-2.5-6.4-39.679.738.639.225.216.22.31.23.1
Op. Profit
Mgn %
-145.100121921.917.115.67.74.31.3
Net Profit
Mgn %
-169.20014.913.416.112.611.23.52.57.1
Debt to
Equity
0.100000.100.10.10.20
Working Cap
Days
1,8270080160173193237423518389
Cash Conv.
Cycle
-3380039103103108154322432222

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 3.10%

Sales growth has been subdued in last 3 years -15.56%

Net Profit has been subdued in last 3 years -52.69%

Sales growth is not so good in last 4 quarters at -18.09%

Latest Financials - Balaxi Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 0.7 2.6
TTM Sales (₹ Cr.) 56.8 276
BVPS (₹.) 23.8 43.1
Reserves (₹ Cr.) 120 227
P/BV 1.47 0.81
PE 48.00 13.31
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 193
Equity (₹ Cr.) 11
Face Value (₹) 2
Industry PE 36.9

Management X-Ray of Balaxi Pharma.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Balaxi Pharma. - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Balaxi Pharma.

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales0001446871011087061
Operating Expenses 00112376884916558
Manufacturing Costs0000000000
Material Costs00010336377825651
Employee Cost 0001223455
Other Costs 0011234533
Operating Profit -0-0-12919171753
Operating Profit Margin (%) -145.0%--11.5%18.9%21.9%17.1%15.6%7.6%4.3%
Other Income 0001123725
Interest 0000000122
Depreciation 0000000110
Exceptional Items 0000000000
Profit Before Tax -0-0-12921202265
Tax -0000355622
Profit After Tax -0-0-12615151644
PAT Margin (%) -169.0%--14.5%14.2%17.4%14.5%15.0%5.2%5.9%
Adjusted EPS (₹)-0.1-0.1-0.51.31.33.02.93.20.70.7
Dividend Payout Ratio (%)0%0%0%0%0%0%3%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 322428435882118128
Share Capital 3333101010101111
Reserves 0-1-1018334872107117
Minority Interest0000000000
Debt0000042111430
Long Term Debt0000000000
Short Term Debt0000042111430
Trade Payables00027171617129
Others Liabilities 000136620107
Total Liabilities 4226386982130154174

Fixed Assets

Gross Block0000013987
Accumulated Depreciation0000000110
Net Fixed Assets 0000012877
CWIP 00000013222
Investments 300002020202025
Inventories0000100110
Trade Receivables0005314852787790
Cash Equivalents 0220401184429
Others Assets 0000207232
Total Assets 4226386982130154174

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0-0-1-2-14139-7-2-8
PBT -0-0-12921202265
Adjustment 0000000123
Changes in Working Capital 000-4-23-5-5-25-4-14
Tax Paid 000-0-1-2-6-5-5-2
Cash Flow From Investing Activity 03-0-0-0-20-7-20-25
Capex -00-0-0-0-1-2-00-0
Net Investments 03000-19-00-0-5
Others 0000-00-5-21-20
Cash Flow From Financing Activity -0-000183-2262817
Net Proceeds from Shares 0000180018263
Net Proceeds from Borrowing 0000000000
Interest Paid 0-0000-0-0-0-1-2
Dividend Paid -0000000-000
Others 0-00004-29316
Net Cash Flow -02-1-23-301726-15

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-2.52-6.37-39.6977.4741.0742.422923.223.662.93
ROCE (%)-2.11-4.69-39.6996.2258.3855.4237.1428.226.085.12
Asset Turnover Ratio0.01003.492.071.631.341.020.490.37
PAT to CFO Conversion(x)N/AN/AN/A-1-2.330.870.6-0.44-0.5-2
Working Capital Days
Receivable Days3500147147167181220403499
Inventory Days0000720563
Payable Days00039506877739677

Balaxi Pharmaceuticals Ltd Stock News

Balaxi Pharmaceuticals Ltd FAQs

The current trading price of Balaxi Pharma. on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Balaxi Pharma. stood at ₹193.1.
The latest P/E ratio of Balaxi Pharma. as of 31-Dec-1969 is 48.00.
The latest P/B ratio of Balaxi Pharma. as of 31-Dec-1969 is 1.47.
The 52-week high of Balaxi Pharma. is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Balaxi Pharma. is ₹56.83 ( Cr.) .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.

Business area of the company

The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products

History and Milestones

2003-07
  • Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
  • Sourcing was from WHO GMP certified plants based in India.
2008-10
  • Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.
2011-13
  • Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
  • Opened first wholesale depot for its ancillary business in Angola.
2014-16
  • In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
  • Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.
2017-19
  • Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
  • Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.
2020
  • Submitted several technical dossiers of Pharmaceutical products in EL Salvador and Honduras for product registrations.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×